Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc. is advancing its innovative portfolio of RNA editing therapies, with specific attention to KRRO-121, an RNA editing drug targeting liver conditions that demonstrates enhanced ammonia clearance, suggesting a significant potential to address unmet medical needs in this sector. The promising preclinical data from both mouse and non-human primate models indicates a robust safety profile and effective intervention, with blockbuster market potentials of approximately $1.5 billion and $2.0 billion for related diseases. Additionally, the company's upcoming IND filing for KRRO-121, scheduled for the second half of 2026, aligns with a clear regulatory pathway, enhancing confidence in Korro Bio’s future growth and valuation.

Bears say

Korro Bio Inc has recently faced significant challenges, highlighted by the negative results from its KRRO-110 program, which led to a notable selloff of its stock and casts doubt on the future of its pipeline. Key risks associated with the company's operations include potential delays in clinical trials, the possibility of unfavorable clinical data from ongoing programs like KRRO-121, and concerns regarding long-term dilution risk for shareholders. Furthermore, the regulatory landscape presents additional uncertainties, as disagreements with authorities such as the FDA and EMA on data interpretations could further hinder the company's progress and market competitiveness.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.